2nd-line Treatment of Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This phase 2 trial aims to evaluate the continued use of bevacizumab with raltitrexed and
oxaliplatin combination versus FOLFOX6 plus bevacizumab in patients with metastatic
colorectal cancer whose disease has progressed after irinotecan-based chemotherapy.